Genetic variation drives cancer cell adaptation to ECM stiffness.
ECM stiffness
cancer
mechanoadaptation
mechanobiology
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
24 Sep 2024
24 Sep 2024
Historique:
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
20
9
2024
Statut:
ppublish
Résumé
The progression of many solid tumors is accompanied by temporal and spatial changes in the stiffness of the extracellular matrix (ECM). Cancer cells adapt to soft and stiff ECM through mechanisms that are not fully understood. It is well known that there is significant genetic heterogeneity from cell to cell in tumors, but how ECM stiffness as a parameter might interact with that genetic variation is not known. Here, we employed experimental evolution to study the response of genetically variable and clonal populations of tumor cells to variable ECM stiffness. Proliferation rates of genetically variable populations cultured on soft ECM increased over a period of several weeks, whereas clonal populations did not evolve. Tracking of DNA barcoded cell lineages revealed that soft ECM consistently selected for the same few variants. These data provide evidence that ECM stiffness exerts natural selection on genetically variable tumor populations. Soft-selected cells were highly migratory, with enriched oncogenic signatures and unusual behaviors such as spreading and traction force generation on ECMs with stiffness as low as 1 kPa. Rho-regulated cell spreading was found to be the directly selected trait, with yes-associated protein 1 translocation to the nucleus mediating fitness on soft ECM. Overall, these data show that genetic variation can drive cancer cell adaptation to ECM stiffness.
Identifiants
pubmed: 39302966
doi: 10.1073/pnas.2403062121
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2403062121Subventions
Organisme : NCI NIH HHS
ID : U01 CA225566
Pays : United States
Organisme : Cancer Prevention and Research Institute of Texas (CPRIT)
ID : RR200043
Organisme : NCI NIH HHS
ID : U01 CA225566
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA253540
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA226258
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255536
Pays : United States
Déclaration de conflit d'intérêts
Competing interests statement:J.D.L. serves as a consultant for AstraZeneca.